PD-1 and CTLA-4 are receptors expressed on the membrane of cytotoxic T lymphocytes and exert antitumor effects by blocking the escape of tumor cells caused by the binding of tumor surface markers to these receptors [4].Tislelizumab is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. This evidence concerns the gene FCGR2A and neoplasm.